BlackRock Inc. boosted its stake in Johnson & Johnson (NYSE: JNJ – Get Rating) by 2.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 200,021,352 shares of the company stock after buying an additional 4,982,885 shares during the period. Johnson & Johnson makes up approximately 0.9% of BlackRock Inc.’s portfolio, making the stock its 10th biggest position. BlackRock Inc. owned about 7.60% of Johnson & Johnson worth $ 34,217,654,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of JNJ. State Street Corp increased its stake in Johnson & Johnson by 1.8% during the fourth quarter. State Street Corp now owns 144,677,639 shares of the company stock worth $ 24,750,004,000 after purchasing an additional 2,492,359 shares during the period. Geode Capital Management LLC increased its stake in shares of Johnson & Johnson by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company stock worth $ 7,576,867,000 after buying an additional 1,084,834 shares during the period. Morgan Stanley increased its stake in shares of Johnson & Johnson by 3.1% during the second quarter. Morgan Stanley now owns 25,066,744 shares of the company stock worth $ 4,129,496,000 after buying an additional 760,796 shares during the period. Legal & General Group Plc increased its stake in shares of Johnson & Johnson by 5.8% during the fourth quarter. Legal & General Group Plc now owns 17,420,146 shares of the company stock worth $ 2,980,062,000 after buying an additional 948,306 shares during the period. Finally, Deutsche Bank AG increased its stake in shares of Johnson & Johnson by 5.2% during the fourth quarter. Deutsche Bank AG now owns 17,214,593 shares of the company stock worth $ 2,944,901,000 after buying an additional 848,662 shares during the period. Hedge funds and other institutional investors own 68.78% of the company stock.
A number of analysts recently weighed in on JNJ shares. Credit Suisse Group upped their target price on shares of Johnson & Johnson from $ 200.00 to $ 205.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Raymond James upped their price target on Johnson & Johnson from $ 195.00 to $ 196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Citigroup lowered their price target on Johnson & Johnson from $ 210.00 to $ 205.00 in a report on Tuesday, May 17th. The Goldman Sachs Group upped their price target on Johnson & Johnson from $ 163.00 to $ 181.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $ 190.50.
JNJ stock opened at $ 170.08 on Friday. The company has a market capitalization of $ 447.55 billion, a P / E ratio of 22.92, a PEG ratio of 3.36 and a beta of 0.66. Johnson & Johnson has a twelve month low of $ 155.72 and a twelve month high of $ 186.69. The business has a 50 day simple moving average of $ 178.35 and a 200-day simple moving average of $ 172.69. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39.
Johnson & Johnson (NYSE: JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, April 19th. The company reported $ 2.67 earnings per share for the quarter, topping the consensus estimate of $ 2.60 by $ 0.07. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The firm had revenue of $ 23.43 billion during the quarter, compared to the consensus estimate of $ 23.62 billion. During the same period last year, the company earned $ 2.59 earnings per share. The company revenue for the quarter was up 5.0% on a year-over-year basis. Research analysts predict that Johnson & Johnson will post 10.23 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th were issued a dividend of $ 1.13 per share. The ex-dividend date of this dividend was Monday, May 23rd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $ 1.06. This represents a $ 4.52 annualized dividend and a dividend yield of 2.66%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 60.92%.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $ 173.00, for a total value of $ 6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at $ 12,336,803. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $ 180.00, for a total value of $ 1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company stock, valued at approximately $ 2,785,140. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 78,161 shares of company stock valued at $ 13,895,302. Corporate insiders own 0.35% of the company stock.
About Johnson & Johnson: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE: JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.